Citrate anticoagulation for continuous venovenous hemofiltration*
Authors:
- Heleen M. Oudemans-Van StraatenHSHeleen M. Oudemans-Van Straaten
- Rob J. BosmanRBRob J. Bosman
- Matty KoopmansMKMatty Koopmans
- Peter H. J. van der VoortPVPeter H. J. van der Voort
- Jos P. J. WesterJWJos P. J. Wester
- Johan I. van der SpoelJSJohan I. van der Spoel
- Lea M. DijksmanLDLea M. Dijksman
- Durk F. ZandstraDZDurk F. Zandstra
- 1 February 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 37 (2) , 545-552
Abstract
Continuous venovenous hemofiltration (CVVH) is applied in critically ill patients with acute renal failure for renal replacement. Heparins used to prevent circuit clotting may cause bleeding. Regional anticoagulation with citrate reduces bleeding, but has metabolic risks. The aim was to compare the safety and efficacy of the two. Randomized, nonblinded, controlled single-center trial. General intensive care unit of a teaching hospital. Adult critically ill patients needing CVVH for acute renal failure and without an increased bleeding risk. Regional anticoagulation with citrate or systemic anticoagulation with the low-molecular weight heparin nadroparin. End points were adverse events necessitating discontinuation of study anticoagulant, transfusion, metabolic and clinical outcomes, and circuit survival. Of the 215 randomized patients, 200 received CVVH per protocol (97 citrate and 103 nadroparin). Adverse events required discontinuation of citrate in two patients (accumulation and clotting) of nadroparin in 20 (bleeding and thrombocytopenia) (p < 0.001). Bleeding occurred in 6 vs. 16 patients (p = 0.08). The median number of red blood cell units transfused per CVVH day was 0.27 (interquartile range, 0.0-0.63) for citrate, 0.36 (interquartile range, 0-0.83) for nadroparin (p = 0.31). Citrate conferred less metabolic alkalosis (p = 0.001) and lower plasma calcium (p < 0.001). Circuit survival was similar. Three-month mortality on intention-to-treat was 48% (citrate) and 63% (nadroparin) (p = 0.03), per protocol 45% and 62% (p = 0.02). Citrate reduced mortality in surgical patients (p = 0.007), sepsis (p = 0.01), higher Sepsis-Related Organ Failure Assessment score (p = 0.006), and lower age (p = 0.009). The efficacy of citrate and nadroparin anticoagulation for CVVH was similar, however, citrate was safer. Unexpectedly, citrate reduced mortality. Less bleeding could only partly explain this benefit, less clotting could not. Post hoc citrate appeared particularly beneficial after surgery, in sepsis and severe multiple organ failure, suggesting interference with inflammation.Keywords
This publication has 37 references indexed in Scilit:
- Clinical review: Patency of the circuit in continuous renal replacement therapyCritical Care, 2007
- Myeloperoxidase as a Marker of Hemodialysis Biocompatibility and Oxidative Stress: The Underestimated Modifying Effects of HeparinAmerican Journal of Kidney Diseases, 2006
- In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranesClinical Therapeutics, 2005
- Calcium signalling: dynamics, homeostasis and remodellingNature Reviews Molecular Cell Biology, 2003
- Citrate clearance in children receiving continuous venovenous renal replacement therapyPediatric Nephrology, 2002
- The Key Role of Anaplerosis and Cataplerosis for Citric Acid Cycle FunctionJournal of Biological Chemistry, 2002
- Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: A double-blind, randomized, crossover studyCritical Care Medicine, 2000
- The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failureIntensive Care Medicine, 1996
- Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patientsKidney International, 1990
- APACHE IICritical Care Medicine, 1985